SPRI | Neuroblastoma (2012 EN)

Discussion in 'Medicine' started by Kanka, Aug 13, 2017.

  1. Kanka

    Kanka Well-Known Member Loyal User

    Messages:
    16,395
    Likes Received:
    485
    Trophy Points:
    83
    [​IMG]

    Author: M.A. Hayat (Editor)
    Full Title: Neuroblastoma
    Publisher: Springer; 1st edition (November 2, 2011)
    Year: 2012
    ISBN-13: 9789400724181 (978-94-007-2418-1), 9789400724174 (978-94-007-2417-4)
    ISBN-10: 9400724187, 9400724179
    Pages: 262
    Language: English
    Genre: Biomedical Sciences: Cancer Research > Pediatric Cancer
    File type: PDF (True, but nonnative Cover)
    Quality: 9/10
    Price: 238.16 €


    Introduction of new technologies and their applications to neuroblastoma diagnosis, treatment, and therapy assessment are explained. Role of molecular ghenetics in diagnosis and therapy for neuroblastoma patients is detailed. Molecular detection of minimal residual neuroblastoma is described. Magnetic resonance imaging and spectroscopy are detailed for diagnosing this solid, extracranial cancer. Targets for therapeutic intervention in neuroblastoma are identified, including targeting multidrug resistance in this cancer. Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. The effectiveness of chemotherapy with oral irinotecan and temozolomide is explained. The role of transcription factors (GATA) in neuroblastoma pregression is also included.

    -------------
     
    Last edited by a moderator: Dec 8, 2019